Publications by authors named "Flavio Araujo Borges-Junior"
Background: Little is currently known about vaccine effectiveness (VE) for either 2 doses of Oxford-AstraZeneca (ChAdOx1) viral vector vaccine or CoronaVac (Instituto Butantan) inactivated viral vaccine followed by a third dose of mRNA vaccine (Pfizer/BioNTech) among healthcare workers (HCWs).
Methods: We conducted a retrospective cohort study among HCWs (aged ≥18 years) working in a private healthcare system in Brazil from January to December 2021. VE was defined as 1 - incidence rate ratio (IRR), with IRR determined using Poisson models with the occurrence of laboratory-confirmed coronavirus disease 2019 (COVID-19) infection as the outcome, adjusting for age, sex, and job type.
Objective: We investigated real-world vaccine effectiveness for Oxford-AstraZeneca (ChAdOx1) and CoronaVac against laboratory-confirmed severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection among healthcare workers (HCWs).
Methods: We conducted a retrospective cohort study among HCWs (aged ≥18 years) working in a private healthcare system in Brazil between January 1, 2021 and August 3, 2021, to assess vaccine effectiveness. We calculated vaccine effectiveness as 1 - rate ratio (RR), with RR determined by adjusting Poisson models with the occurrence of SARS-CoV-2 infection as the outcome and the vaccination status as the main variable.
Caring for the Workforce of a Health System During the COVID-19 Epidemic in Brazil: Strategies of Surveillance and Expansion of Access to Care.
J Occup Environ Med
October 2020
Objectives: To describe the strategies to monitor and expand access to care for a health system workers in the first 2 months of the COVID-19 epidemic in Brazil.
Methods: Description of the implemented strategy based on the guidelines developed to address the surveillance and care of a large health system's workforce in the COVID-19 epidemic.
Results: During phase 1, the surveillance strategy focused on monitoring suspected cases among employees.
Article Synopsis
- Dipeptidyl peptidase IV (DPPIV) inhibitors, like sitagliptin, not only help lower blood sugar but also provide kidney protection and may reduce cardiac dysfunction in chronic kidney disease (CKD).
- In a rat study, DPPIV inhibition improved heart health by decreasing issues like cardiac hypertrophy and fibrosis, as well as mitigating diastolic dysfunction associated with kidney failure.
- The research suggests that the positive effects of DPPIV inhibitors are linked to restoring balance in the heart's renin-angiotensin system, indicating a potential connection between DPPIV and heart-kidney health issues.